Search Results - "Shulkin, Barry"

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial by Mody, Rajen, MD, Naranjo, Arlene, PhD, Van Ryn, Collin, MS, Yu, Alice L, Prof, London, Wendy B, PhD, Shulkin, Barry L, Prof, Parisi, Marguerite T, Prof, Servaes, Sabah-E-Noor, MD, Diccianni, Mitchell B, PhD, Sondel, Paul M, Prof, Bender, Julia G, MD, Maris, John M, Prof, Park, Julie R, Prof, Bagatell, Rochelle, Dr

“…Summary Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in…”
Get full text

Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma by McCarten, Kathleen M., Nadel, Helen R., Shulkin, Barry L., Cho, Steve Y.

“…Hodgkin lymphoma and non-Hodgkin lymphoma are common malignancies in children and are now highly treatable. Imaging plays a major role in diagnosis, staging…”
Get full text

PET/CT and PET/MR in Soft Tissue Sarcoma: An Update by Khalatbari, Hedieh, Shulkin, Barry L, Parisi, Marguerite T

“…Soft tissue sarcomas account for 6%-8% of pediatric cancers. The rhabdomyosarcoma family is the most frequent soft tissue sarcoma in this age group accounting…”
Get full text

Pediatric Rhabdomyosarcoma Protocols Should Include More Detailed Imaging Guidelines to Ensure Homogeneous Response Assessment by Schoot, Reineke A, Shulkin, Barry L, van Rijn, Rick R, von Kalle, Thekla

Get full text

Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity by Khalatbari, Hedieh, Shulkin, Barry L., Parisi, Marguerite T.

“…The most common indication for 18F-FDG PET/CT is tumor imaging, which may be performed for initial diagnosis, staging, therapeutic response monitoring,…”
Get full text

Nuclear Medicine Imaging Tools in Fever of Unknown Origin: Time for a Revisit and Appropriate Use Criteria by Wright, William F, Kandiah, Sheetal, Brady, Rebecca, Shulkin, Barry L, Palestro, Christopher J, Jain, Sanjay K

“…Fever of unknown origin (FUO) is a clinical conundrum for patients and clinicians alike, and imaging studies are often performed as part of the diagnostic…”
Get full text

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 by Yu, Alice L, Gilman, Andrew L, Ozkaynak, M Fevzi, Naranjo, Arlene, Diccianni, Mitchell B, Gan, Jacek, Hank, Jacquelyn A, Batova, Ayse, London, Wendy B, Tenney, Sheena C, Smith, Malcolm, Shulkin, Barry L, Parisi, Marguerite, Matthay, Katherine K, Cohn, Susan L, Maris, John M, Bagatell, Rochelle, Park, Julie R, Sondel, Paul M

“…Previously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for…”
Get full text

18F-FDG PET/CT in the Management of Osteosarcoma by Oh, Chiwoo, Bishop, Michael W, Cho, Steve Y, Im, Hyung-Jun, Shulkin, Barry L

Get full text

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group by Mody, Rajen, Yu, Alice L, Naranjo, Arlene, Zhang, Fan F, London, Wendy B, Shulkin, Barry L, Parisi, Marguerite T, Servaes, Sabah-E-Noor, Diccianni, Mitchell B, Hank, Jacquelyn A, Felder, Mildred, Birstler, Jennifer, Sondel, Paul M, Asgharzadeh, Shahab, Glade-Bender, Julia, Katzenstein, Howard, Maris, John M, Park, Julie R, Bagatell, Rochelle

“…The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in…”
Get full text

Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A by Furman, Wayne L, McCarville, Beth, Shulkin, Barry L, Davidoff, Andrew, Krasin, Matthew, Hsu, Chia-Wei, Pan, Haitao, Wu, Jianrong, Brennan, Rachel, Bishop, Michael W, Helmig, Sara, Stewart, Elizabeth, Navid, Fariba, Triplett, Brandon, Santana, Victor, Santiago, Teresa, Hank, Jacquelyn A, Gillies, Stephen D, Yu, Alice, Sondel, Paul M, Leung, Wing H, Pappo, Alberto, Federico, Sara M

“…We evaluated whether combining a humanized antidisialoganglioside monoclonal antibody (hu14.18K322A) throughout therapy improves early response and outcomes in…”
Get full text

Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project by BRISSE, Hervé J, MCCARVILLE, M. Beth, LEWINGTON, Valerie J, SARNACKI, Sabine, HERO, Barbara, KANEKO, Michio, LONDON, Wendy B, PEARSON, Andrew D. J, COHN, Susan L, MONCLAIR, Tom, GRANATA, Claudio, BARBARA KRUG, K, WOOTTON-GORGES, Sandra L, KANEGAWA, Kimio, GIAMMARILE, Francesco, SCHMIDT, Matthias, SHULKIN, Barry L, MATTHAY, Katherine K

“…Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously without any therapy, while others progress with a fatal outcome despite the…”
Get full text

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma by Federico, Sara M, McCarville, M Beth, Shulkin, Barry L, Sondel, Paul M, Hank, Jacquelyn A, Hutson, Paul, Meagher, Michael, Shafer, Aaron, Ng, Catherine Y, Leung, Wing, Janssen, William E, Wu, Jianrong, Mao, Shenghua, Brennan, Rachel C, Santana, Victor M, Pappo, Alberto S, Furman, Wayne L

“…Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of…”
Get full text

High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma by Jha, Abhishek, Taïeb, David, Carrasquillo, Jorge A., Pryma, Daniel A., Patel, Mayank, Millo, Corina, de Herder, Wouter W., Del Rivero, Jaydira, Crona, Joakim, Shulkin, Barry L., Virgolini, Irene, Chen, Alice P., Mittal, Bhagwant R., Basu, Sandip, Dillon, Joseph S., Hope, Thomas A., Mari Aparici, Carina, Iagaru, Andrei H., Hicks, Rodney J., Avram, Anca M., Strosberg, Jonathan R., Civelek, Ali Cahid, Lin, Frank I., Pandit-Taskar, Neeta, Pacak, Karel

“…Abstract Targeted radionuclide therapies (TRT) using 131I-metaiodobenzylguanidine (131I-MIBG) and peptide receptor radionuclide therapy (177Lu or 90Y)…”
Get full text

Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention by Smallwood, Heather S., Duan, Susu, Morfouace, Marie, Rezinciuc, Svetlana, Shulkin, Barry L., Shelat, Anang, Zink, Erika E., Milasta, Sandra, Bajracharya, Resha, Oluwaseum, Ajayi J., Roussel, Martine F., Green, Douglas R., Pasa-Tolic, Ljiljana, Thomas, Paul G.

“…Influenza is a worldwide health and financial burden posing a significant risk to the immune-compromised, obese, diabetic, elderly, and pediatric populations…”
Get full text

18 F-FDG PET/CT in the Management of Osteosarcoma by Oh, Chiwoo, Bishop, Michael W, Cho, Steve Y, Im, Hyung-Jun, Shulkin, Barry L

“…Osteosarcoma is the most common type of primary malignant bone tumor. F-FDG PET/CT is useful for staging, detecting recurrence, monitoring response to…”
Get full text

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial by Weiss, Aaron R, Chen, Yen-Lin, Scharschmidt, Thomas J, Chi, Yueh-Yun, Tian, Jing, Black, Jennifer O, Davis, Jessica L, Fanburg-Smith, Julie C, Zambrano, Eduardo, Anderson, James, Arens, Robin, Binitie, Odion, Choy, Edwin, Davis, Justin W, Hayes-Jordan, Andrea, Kao, Simon C, Kayton, Mark L, Kessel, Sandy, Lim, Ruth, Meyer, William H, Million, Lynn, Okuno, Scott H, Ostrenga, Andrew, Parisi, Marguerite T, Pryma, Daniel A, Randall, R Lor, Rosen, Mark A, Schlapkohl, Mary, Shulkin, Barry L, Smith, Ethan A, Sorger, Joel I, Terezakis, Stephanie, Hawkins, Douglas S, Spunt, Sheri L, Wang, Dian

“…Outcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy. We investigated whether the addition of pazopanib to…”
Get full text

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group by Malempati, Suman, Weigel, Brenda J, Chi, Yueh-Yun, Tian, Jing, Anderson, James R, Parham, David M, Teot, Lisa A, Rodeberg, David A, Yock, Torunn I, Shulkin, Barry L, Spunt, Sheri L, Meyer, William H, Hawkins, Douglas S

“…The outcome for patients with metastatic rhabdomyosarcoma (RMS) remains poor. A previous Children's Oncology Group (COG) study (ARST0431) for patients with…”
Get full text

Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group by Yanik, Gregory A, Parisi, Marguerite T, Shulkin, Barry L, Naranjo, Arlene, Kreissman, Susan G, London, Wendy B, Villablanca, Judith G, Maris, John M, Park, Julie R, Cohn, Susan L, McGrady, Patrick, Matthay, Katherine K

“…Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and specific marker for detecting neuroblastoma. A semiquantitative mIBG score (Curie score…”
Get full text

A retrospective investigation of the relationship between neuroblastoma response to anti‐GD2 monoclonal antibodies and exposure to opioids for pain management by Morgan, Kyle J., Dudas, Andrew, Furman, Wayne L., McCarville, M. Beth, Shulkin, Barry L., Lu, Zhaohua, Darji, Himani, Anghelescu, Doralina L.

“…Objective Recent increased awareness and research studies reflect possible associations between opioid exposure and cancer outcomes. Children with…”
Get full text

A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma by Furman, Wayne L, Federico, Sara M, McCarville, Mary Beth, Shulkin, Barry L, Davidoff, Andrew M, Krasin, Matthew J, Sahr, Natasha, Sykes, April, Wu, Jianrong, Brennan, Rachel C, Bishop, Michael William, Helmig, Sara, Stewart, Elizabeth, Navid, Fariba, Triplett, Brandon, Santana, Victor M, Bahrami, Armita, Anthony, Gwendolyn, Yu, Alice L, Hank, Jacquelyn, Gillies, Stephen D, Sondel, Paul M, Leung, Wing H, Pappo, Alberto S

“…We sought to evaluate whether combining a humanized antidisialoganglioside mAb (hu14.18K322A) with induction chemotherapy improves early responses and outcomes…”
Get full text